Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder
- PMID: 15950015
- DOI: 10.1016/j.biopsych.2004.11.006
Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder
Abstract
Methylphenidate hydrochloride (MP) is an effective treatment for attention-deficit/hyperactivity disorder (ADHD), a common neurobehavioral disorder of childhood onset characterized by inattention, hyperactivity, and distractibility. Methylphenidate hydrochloride blocks the dopamine transporters (DAT), the main mechanism for removing dopamine (DA) from the synapse, is believed to be involved in its therapeutic properties. However, the mechanism(s) by which increases in DA improve symptomatology in ADHD are not completely understood. Our studies of the dopaminergic effects of MP in the human brain using positron emission tomography (PET) have shown that MP blocks DAT, and that extracellular DA increases in proportion to the level of blockade and the rate of DA release (modulated by DA cell firing). These DA increases are greater when MP is given concomitantly with a salient stimulus than with a neutral stimulus, documenting the context dependency of MP effects. Additionally, MP-induced increases in DA are associated with an enhanced perception of the stimulus as salient. We postulate the MP's therapeutic effects are due in part to its ability to enhance the magnitude of DA increases induced by stimuli that by themselves generate weak responses, enhancing their saliency and the attention and interest they elicit. We postulate that these effects would improve school performance.
Similar articles
-
Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53. doi: 10.1097/JCP.0b013e318173312f. J Clin Psychopharmacol. 2008. PMID: 18480677 Review.
-
Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.Neuroimage. 2008 Jul 1;41(3):718-27. doi: 10.1016/j.neuroimage.2008.02.025. Epub 2008 Feb 29. Neuroimage. 2008. PMID: 18424180
-
[Alterations in the pattern of dopaminergic markers in attention-deficit/hyperactivity disorder].Rev Neurol. 2006 Feb 13;42 Suppl 2:S19-23. Rev Neurol. 2006. PMID: 16555214 Review. Spanish.
-
Mechanism of action of methylphenidate: insights from PET imaging studies.J Atten Disord. 2002;6 Suppl 1:S31-43. doi: 10.1177/070674370200601s05. J Atten Disord. 2002. PMID: 12685517
-
Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder.Neuroimage. 2005 Apr 15;25(3):868-76. doi: 10.1016/j.neuroimage.2004.11.031. Neuroimage. 2005. PMID: 15808987
Cited by
-
Brain iron levels in attention-deficit/hyperactivity disorder normalize as a function of psychostimulant treatment duration.Neuroimage Clin. 2019;24:101993. doi: 10.1016/j.nicl.2019.101993. Epub 2019 Aug 26. Neuroimage Clin. 2019. PMID: 31479897 Free PMC article.
-
The ability of the mesocortical dopamine system to operate in distinct temporal modes.Psychopharmacology (Berl). 2007 Apr;191(3):609-25. doi: 10.1007/s00213-006-0527-8. Epub 2006 Nov 4. Psychopharmacology (Berl). 2007. PMID: 17086392 Free PMC article. Review.
-
The Effects of Methylphenidate (Ritalin) on the Neurophysiology of the Monkey Caudal Prefrontal Cortex.eNeuro. 2019 Mar 4;6(1):ENEURO.0371-18.2018. doi: 10.1523/ENEURO.0371-18.2018. eCollection 2019 Jan-Feb. eNeuro. 2019. PMID: 30847388 Free PMC article.
-
The effects of methylphenidate on cognitive control in active methamphetamine dependence using functional magnetic resonance imaging.Front Psychiatry. 2014 Mar 6;5:20. doi: 10.3389/fpsyt.2014.00020. eCollection 2014. Front Psychiatry. 2014. PMID: 24639656 Free PMC article.
-
Methylphenidate alleviates cognitive dysfunction from early Mn exposure: Role of catecholaminergic receptors.bioRxiv [Preprint]. 2023 Oct 4:2023.06.27.546786. doi: 10.1101/2023.06.27.546786. bioRxiv. 2023. Update in: Prog Neuropsychopharmacol Biol Psychiatry. 2024 Apr 20;131:110949. doi: 10.1016/j.pnpbp.2024.110949. PMID: 37873333 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical